Clinical trial CAMBRIA-2
A phase III, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) vs standard endocrine therapy (aromatase inhibitor or Tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2023-504031-41-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05952557 |
| Last update |